However, while the response rate was significantly higher than with placebo, the relative change in BASDAI50 was relatively modest and not of the same magnitude typically seen with anti-TNF drugs, he said.
"So I think the jury is still out on the anti-IL17," he concluded.
Dr. Inman disclosed that he is a consultant for Abbott Laboratories, Merck , Pfizer, and Sanofi-Aventis.